33 terminated. 33 Phase 2, 9 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Terminated 33 |
| Phase 1 | 9 | Terminated 9 |
| Phase 3 | 1 | Terminated 1 |
Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| AB1 in Adult Patients With Sickle Cell Disease (SCD) AB1 - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Nirmish Shah | 16 | 2022-12-05 | 2026-10-15 |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1 / Phase 2 | Terminated | University of Illinois at Chicago | 12 | 2021-03-16 | 2025-04-03 |
| A Study of IMR-687 in Subjects With Sickle Cell Disease IMR-687, Placebo - Sickle Cell Disease | Phase 2 | Terminated | Cardurion Pharmaceuticals, Inc. | 115 | 2020-08-13 | 2025-05-15 |
| Imatinib for Pain in Sickle Cell Anemia Imatinib Mesylate - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Indiana University | 7 | 2020-02-26 | 2026-01-29 |
| Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD Voxelotor - Sickle Cell Disease | Phase 2 | Terminated | Pfizer | 6 | 2020-01-09 | 2023-11-21 |
| Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere Hydroxyurea, Hydroxyurea Oral Capsule - Sickle Cell Disease, Thalassemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 1 | 2019-06-10 | 2022-03-18 |
| Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases Blood and Marrow Transplant - Sickle Cell Disease, Thalassemia | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 5 | 2018-07-02 | 2024-07-12 |
| Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers Topical Sodium Nitrite, Placebo - Sickle Cell Disease | Phase 2 | Terminated | caterina P minniti | 18 | 2018-04-06 | 2025-05-07 |
| Omega-3 Fatty Acids in Sickle Cell Disease SCD-Omegatex™ - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Robin E. Miller | 4 | 2018-01-25 | 2020-10-19 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease Voxelotor - Sickle Cell Disease | Phase 2 | Terminated | Pfizer | 147 | 2016-07-05 | 2025-08-15 |
| Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies CordIn - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 1 | 2016-04-04 | 2019-06-26 |
| Macitentan in Pulmonary Hypertension of Sickle Cell Disease macitentan - Pulmonary Hypertension, Sickle Cell Disease | Phase 2 | Terminated | Boston University | 4 | 2015-07-01 | 2020-12-08 |
| Preventing Sickle Cell Kidney Disease Losartan - Anemia, Sickle Cell, Sickle Cell Disease | Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2015-04-01 | 2024-04-03 |
| Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome Unfractionated heparin - Acute Chest Syndrome, Sickle Cell Disease | Phase 2 | Terminated | Craig Seaman | 7 | 2014-05-01 | 2019-07-16 |
| SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD Haploidentical Transplant, Alemtuzumab, Total Body Irradiation - Sickle Cell Disease | Phase 2 | Terminated | Damiano Rondelli, MD | 2 | 2014-04-10 | 2019-08-28 |
| Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease Aes-103, Placebo - Sickle Cell Disease | Phase 2 | Terminated | Baxalta now part of Shire | 35 | 2013-12-03 | 2021-05-25 |
Showing 20 of 33. Sign in to see all of them.
Anemia, Sickle Cell (33) · Hypertension, Pulmonary (4) · Thalassemia (4) · Vaso-Occlusive Crises (3) · beta-Thalassemia (2) · Acute Chest Syndrome (1) · Anemia (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Hemolytic (1) · Congenital amegakaryocytic thrombocytopenia (1) · Granulomatous Disease, Chronic (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Hemoglobinuria, Paroxysmal (1)
Anemia, Hemolytic, Congenital (33) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (33) · Genetic Diseases, Inborn (33) · Hemic and Lymphatic Diseases (33) · Anemia (32) · Anemia, Hemolytic (32) · Hematologic Diseases (32) · Hemoglobinopathies (32) · Cardiovascular Diseases (6) · Vascular Diseases (6) · Respiratory Tract Diseases (5) · Hypertension (4) · Lung Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (2)
Cyclophosphamide (4) · fludarabine phosphate (3) · voxelotor (3) · Hydroxyurea (2) · Mycophenolic Acid (2) · Sirolimus (2) · Sodium Nitrite (2) · Whole-Body Irradiation (2) · thymoglobulin (2) · 2,2-dimethylbutyric acid (1) · 5-hydroxymethylfurfural (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Busulfan (1)
Pfizer (3) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Anthera Pharmaceuticals (1) · Baxalta now part of Shire (1) · Boston Children's Hospital (1) · Boston University (1) · Cardurion Pharmaceuticals, Inc. (1) · Children's Hospital Los Angeles (1) · Connecticut Children's Medical Center (1) · Craig Seaman (1) · Damiano Rondelli, MD (1) · Dana-Farber Cancer Institute (1) · Ensoma (1) · Fulcrum Therapeutics (1) · Gamida Cell ltd (1)
United States (31) · United Kingdom (5) · Lebanon (3) · Canada (1) · Egypt (1) · France (1) · Ghana (1) · Greece (1) · Italy (1) · Jamaica (1) · Kenya (1) · Morocco (1) · Netherlands (1) · Nigeria (1) · Oman (1)
Allistair Abraham, MD (1) · Caterina Minniti, M.D. (1) · Christen L Ebens, MD, MPH (1) · Craig D Seaman, MD (1) · Damiano Rondelli, MD (1) · Debra Weiner, MD, PhD (1) · Elizabeth Klings, MD (1) · Franco Locatelli, MD (1) · Javier Bolanos-Meade, MD (1) · Jean-Hugues Dalle, MD (1) · Jeffrey D Lebensburger, DO, MSPH (1) · Jeremie Estepp, MD (1) · Ji Hyun Lee, MD, MPH (1) · Kenneth Attie, MD (1)
PMID 21527519, PMID 21900080, PMID 22983573, PMID 23973010, PMID 24677033, PMID 24988120, PMID 30878319, PMID 31322833, PMID 34014839, PMID 34990411, PMID 35451176, PMID 37254256, PMID 37439373, PMID 39428602, PMID 41569644, PMID 42224366
2019 (1), K23HL127100 (1), P01CA015396 (1), P20GM109021 (1), P30CA006973 (1)